NKTR
Nektar Therapeutics
43.60$
-7.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
Nektar Therapeutics (NKTR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -209 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.8 | 5.0 | -19 | -15 | -36 | -51 | -75 | -76 | -78 | -78 | -93 | 146 | -146 | 40 | -56 | -114 | -130 | -39 | -142 | -73 | -117 | -80 | 718 | -329 | -313 | -413 | -304 | -193 | -176 | -209 | |
| 1.2 | 2.4 | 3.6 | 7.3 | 10 | 40 | 19 | 18 | 19 | 26 | 33 | 28 | 22 | 15 | 17 | 15 | 15 | 14 | 13 | 13 | 15 | 15 | 11 | 13 | 14 | 14 | 13 | 7.8 | 4.4 | -4.5 | |
| – | – | – | – | 0.9 | 0.9 | 0.5 | 0.2 | 1.2 | 1.9 | 0.0 | 15 | 9.9 | 10 | 17 | 19 | 16 | 18 | 17 | 20 | 26 | 37 | 88 | 100 | 94 | 95 | 57 | 33 | 22 | 13 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 20 | 26 | 19 | 15 | 17 | 13 | 24 | 76 | 89 | 76 | 120 | 51 | – | – | – | |
| 2.8 | 12 | -4.7 | 5.2 | 3.6 | 8.0 | 10 | -19 | -7.7 | 4.6 | -8.9 | 107 | -27 | 118 | -65 | -15 | 1.6 | 91 | -116 | -35 | 7.9 | -38 | -39 | 22 | 17 | -23 | 0.5 | -20 | -6.2 | -37 | |
| 2.2 | 17 | 35 | 21 | 54 | 34 | 16 | 19 | 27 | 18 | 23 | 33 | 19 | 21 | 31 | 9.7 | 11 | 4.1 | 10.0 | 11 | 6.4 | 9.7 | 14 | 26 | 7.3 | 15 | 5.7 | 0.9 | 1.5 | 0.2 | |
| -3.8 | -85 | -6.5 | -82 | -300 | -77 | 40 | 4.1 | -89 | 32 | -117 | -33 | 275 | -149 | 17 | -112 | 113 | 50 | -38 | -14 | -82 | -29 | -1,380 | 207 | 496 | 203 | 366 | 140 | 143 | -1.2 | |
| – | – | – | – | – | – | – | – | 6.7 | 1.3 | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | 1.3 | 1.2 | – | – | – | – | – | 224 | 4.1 | 8.2 | 164 | 32 | 210 | 60 | 852 | 23 | 23 | 33 | – | 0.0 | -3.0 | 0.0 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -2.0 | -97 | -3.0 | -3.5 | 99 | -5.9 | -5.1 | -250 | -250 | -250 | 0.0 | 0.0 | – | – | – | |
| 24 | 76 | 37 | 106 | 438 | 23 | 39 | 101 | 207 | 275 | 12 | -102 | -50 | 3.5 | 7.5 | 222 | 27 | 2.2 | 153 | 131 | 204 | 54 | 852 | 23 | -80 | 36 | 1.5 | 0.0 | 42 | 181 | |
| 15 | -3.6 | 11 | 8.5 | 103 | -105 | 4.1 | 29 | 40 | 229 | -198 | 13 | 79 | -106 | -32 | -2.4 | 10 | 14 | -27 | 43 | 4.1 | -55 | 190 | -99 | 103 | -174 | 63 | -53 | 9.0 | -29 | |
| -8.0 | -12 | -54 | -36 | -90 | -85 | -91 | -95 | -105 | -96 | -115 | 114 | -165 | 19 | -87 | -123 | -140 | -43 | -152 | -84 | -123 | -90 | 704 | -355 | -321 | -428 | -310 | -193 | -177 | -209 |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.